Weighted Average Number of Shares Outstanding, Basic of Adaptimmune Therapeutics PLC from 30 Sep 2017 to 30 Jun 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Adaptimmune Therapeutics PLC quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 30 Sep 2017 to 30 Jun 2025.
  • Adaptimmune Therapeutics PLC Weighted Average Number of Shares Outstanding, Basic for the quarter ending 30 Jun 2025 was 1,584,522,868, a 3.3% increase year-over-year.
  • Adaptimmune Therapeutics PLC annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 1,513,810,852, a 25% increase from 2023.
  • Adaptimmune Therapeutics PLC annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 1,206,440,978, a 25% increase from 2022.
  • Adaptimmune Therapeutics PLC annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 967,242,403, a 3.5% increase from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Adaptimmune Therapeutics PLC Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 1,584,522,868 +50,991,031 +3.3% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 1,542,159,622 +90,917,961 +6.3% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 1,513,810,852 +307,369,874 +25% 01 Oct 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q3 2024 1,534,613,977 +176,764,321 +13% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 1,533,531,837 +425,364,877 +38% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 1,451,241,661 +459,911,259 +46% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 1,206,440,978 +239,198,575 +25% 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 1,357,849,656 +377,058,542 +38% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 1,108,166,960 +145,372,888 +15% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 991,330,402 +51,301,155 +5.5% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 967,242,403 +32,409,386 +3.5% 01 Oct 2022 31 Dec 2022 10-K 24 Mar 2025 2024 FY
Q3 2022 980,791,114 +44,190,466 +4.7% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 962,794,072 +28,565,977 +3.1% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 940,029,247 +8,940,437 +0.96% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 934,833,017 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2024 2023 FY
Q3 2021 936,600,648 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 934,228,095 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 931,088,810 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q3 2019 630,866,800 +48,861,846 +8.4% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2019 2019 Q3
Q1 2019 627,945,243 +65,563,248 +12% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2019 2019 Q1
Q3 2018 582,004,954 +20,765,090 +3.7% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q1 2018 562,381,995 01 Jan 2018 31 Mar 2018 10-Q 06 May 2019 2019 Q1
Q3 2017 561,239,864 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3

Adaptimmune Therapeutics PLC Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 1,513,810,852 +307,369,874 +25% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 1,206,440,978 +239,198,575 +25% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 967,242,403 +32,409,386 +3.5% 01 Jan 2022 31 Dec 2022 10-K 24 Mar 2025 2024 FY
2021 934,833,017 +80,049,254 +9.4% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2024 2023 FY
2020 854,783,763 +224,978,545 +36% 01 Jan 2020 31 Dec 2020 10-K 06 Mar 2023 2022 FY
2019 629,805,218 01 Jan 2019 31 Dec 2019 10-K 14 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.